A comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis

Dendritic cell (DC)-based immunotherapy has potential for use in the treatment of cancer, infections and transplantation. Generating large numbers of DC from haemopoietic progenitor cells (HPC) is a key step in this process, often achieved by the aphaeresis of HPC, following their mobilization from...

Full description

Bibliographic Details
Main Author: Decatris, Marios Petrou
Published: University of Leicester 2003
Subjects:
616
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.275487
id ndltd-bl.uk-oai-ethos.bl.uk-275487
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-2754872016-12-08T03:23:36ZA comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresisDecatris, Marios Petrou2003Dendritic cell (DC)-based immunotherapy has potential for use in the treatment of cancer, infections and transplantation. Generating large numbers of DC from haemopoietic progenitor cells (HPC) is a key step in this process, often achieved by the aphaeresis of HPC, following their mobilization from the bone marrow into peripheral blood (PB) with chemotherapy and growth factor support (usually, granulocyte-colony stimulating factor, G-CSF). The objective of this work was to identify the optimum time for leucaphaeresis of DC progenitors. An established clonogenic assay specific for colony-forming cell (CFC) DC was used and validated with linearity, dose-response experiments and morphological confirmation. The optimal numbers of mononuclear and CD34+ (or AC133+) cells for plating were 5x104 and l-2xl03 respectively. The optimal concentrations of recombinant cytokines were also determined. Kinetic studies were done in patients with solid tumours, and HPC mobilization was achieved with conventional chemotherapy and G-CSF. The best time for harvesting large numbers of DC progenitors was when the leucocyte count rose rapidly from its nadir at a median 10 days (range 7-13) post chemotherapy. Comparative studies identified mobilized PB as the richest source of CFC-DC (mean, 1,481/ ml PB), with at least, 1.5-fold more progenitors per unit volume than cord blood (CB). These data suggest that venesection alone could provide sufficient CFC-DC to generate mature DC, after ex vivo culture and expansion. This might obviate the need for leucaphaeresis thus making DC-based immunotherapy potentially more widely available. In all the haemopoietic tissues examined the majority of DC and granulo (G)-monocytic (M) progenitors, was found within the CD34+AC133+ cell population. It is concluded that the kinetics of mobilization of CFC-DC are very similar to those of other HPC like CFC- GM and erythroid progenitors. This has important implications for designing immunotherapy protocols to isolate DC precursors from CD34+ HPC for ultimate use in DC-based immunotherapy.616MedicineUniversity of Leicesterhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.275487http://hdl.handle.net/2381/29456Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 616
Medicine
spellingShingle 616
Medicine
Decatris, Marios Petrou
A comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis
description Dendritic cell (DC)-based immunotherapy has potential for use in the treatment of cancer, infections and transplantation. Generating large numbers of DC from haemopoietic progenitor cells (HPC) is a key step in this process, often achieved by the aphaeresis of HPC, following their mobilization from the bone marrow into peripheral blood (PB) with chemotherapy and growth factor support (usually, granulocyte-colony stimulating factor, G-CSF). The objective of this work was to identify the optimum time for leucaphaeresis of DC progenitors. An established clonogenic assay specific for colony-forming cell (CFC) DC was used and validated with linearity, dose-response experiments and morphological confirmation. The optimal numbers of mononuclear and CD34+ (or AC133+) cells for plating were 5x104 and l-2xl03 respectively. The optimal concentrations of recombinant cytokines were also determined. Kinetic studies were done in patients with solid tumours, and HPC mobilization was achieved with conventional chemotherapy and G-CSF. The best time for harvesting large numbers of DC progenitors was when the leucocyte count rose rapidly from its nadir at a median 10 days (range 7-13) post chemotherapy. Comparative studies identified mobilized PB as the richest source of CFC-DC (mean, 1,481/ ml PB), with at least, 1.5-fold more progenitors per unit volume than cord blood (CB). These data suggest that venesection alone could provide sufficient CFC-DC to generate mature DC, after ex vivo culture and expansion. This might obviate the need for leucaphaeresis thus making DC-based immunotherapy potentially more widely available. In all the haemopoietic tissues examined the majority of DC and granulo (G)-monocytic (M) progenitors, was found within the CD34+AC133+ cell population. It is concluded that the kinetics of mobilization of CFC-DC are very similar to those of other HPC like CFC- GM and erythroid progenitors. This has important implications for designing immunotherapy protocols to isolate DC precursors from CD34+ HPC for ultimate use in DC-based immunotherapy.
author Decatris, Marios Petrou
author_facet Decatris, Marios Petrou
author_sort Decatris, Marios Petrou
title A comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis
title_short A comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis
title_full A comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis
title_fullStr A comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis
title_full_unstemmed A comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis
title_sort comparative quantitative study of human myeloid dendritic cell progenitors in cord blood, bone marrow, peripheral blood and their mobilization kinetics in the peripheral blood of cancer patients undergoing leucaphaeresis
publisher University of Leicester
publishDate 2003
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.275487
work_keys_str_mv AT decatrismariospetrou acomparativequantitativestudyofhumanmyeloiddendriticcellprogenitorsincordbloodbonemarrowperipheralbloodandtheirmobilizationkineticsintheperipheralbloodofcancerpatientsundergoingleucaphaeresis
AT decatrismariospetrou comparativequantitativestudyofhumanmyeloiddendriticcellprogenitorsincordbloodbonemarrowperipheralbloodandtheirmobilizationkineticsintheperipheralbloodofcancerpatientsundergoingleucaphaeresis
_version_ 1718399965216112640